Condition: Endometrial Cancer · Sponsor: Fondazione IRCCS Istituto Nazionale dei Tumori, Milano
The clinical trial concerns the use of an innovative \"anti-emetic\" drug (that is, anti-vomiting and nausea) in subjects affected by endometrial cancer. It is addressed to patients who have never received chemotherapy before and are about to start a treatment with platinum and taxanes with or without immunotherapy for endometrial cancer. The primary objective of the study is to learn if the drug is able to avoid the occurrence of vomiting and post- nausea chemotherapy within 120 hours after cycle 1 with carboplatin and paclitaxel with or without immunotherapy. Partecipants will take the drug before the chemotherapy/immunotherapy (single dose at day one of each cycle of therapy, that is one capsule before treatment). The entire duration of participation in the study may extend to the fourth cycle of chemotherapy/immunotherapy. Patients will fill in questionnaires and keep a diary of the number and intensity of symptoms (vomiting and nausea).
This description comes directly from the study's public registry record.
Monika Ducceschi, MD · +39 02 2390 2342 · monika.ducceschi@istitutotumori.mi.it
Mara Mantiero, MD · +39 02 2390 2342 · mara.mantiero@istitutotumori.mi.it
Always discuss trial participation with your own doctor first.
| ASST Spedali Civili di Brescia | Brescia, BS, Italy | Not Yet Recruiting |
| ASST Lecco - A. Manzoni Hospital | Lecco, LC, Italy | Recruiting |
| Istituto Oncologico Veneto | Padova, PD, Italy | Recruiting |
| Centro di Riferimento Oncologico (CRO) IRCCS | Aviano, PN, Italy | Not Yet Recruiting |
| Azienda Ospedaliera Ordine Mauriziano di Torino | Torino, TO, Italy | Active Not Recruiting |
| AOU Città della Salute e della Scienza di Torino | Torino, TO, Italy | Not Yet Recruiting |
| Fondazione IRCCS Istituto Nazionale dei Tumori | Milan, Italy | Recruiting |
| Istituto Europeo di Oncologia | Milan, Italy | Active Not Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06726291